Innovative Genomic approach

The medical community has traditionally categorized and addressed cancer based on its anatomical location, such as breast, lung, or leukemia.

However, in a significant shift, the FDA has recently begun approving treatments that are determined by the genetic characteristics of the cancer, rather than its site of origin.

Advancements in DNA sequencing have made it faster and more affordable for patients to gain insights into their genetic codes, enabling a deeper understanding of how genetic alterations can contribute to diseases like cancer.

This sequencing technology empowers us to identify similarities between genetic mutations in different types of cancer. For example, a genetic mutation found in breast cancer may share common features with one associated with colon cancer. In such cases, a patient with this form of breast cancer might benefit from a treatment typically used for colon cancer, rather than the conventional breast cancer therapies.

This innovative approach represents a promising path toward effectively treating cancer and other life-threatening illnesses.